AI assistant
RELMADA THERAPEUTICS, INC. — Director's Dealing 2021
Jul 16, 2021
34465_dirs_2021-07-16_d509e6e8-daf2-426b-b829-eefb659a1994.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: RELMADA THERAPEUTICS, INC. (RLMD)
CIK: 0001553643
Period of Report: 2021-07-15
Reporting Person: CASAMENTO CHARLES J (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-07-15 | Common Stock | S | 2136 | $31.0262 | Disposed | 5854 | Direct |
| 2021-07-15 | Common Stock | S | 1164 | $32.4883 | Disposed | 4700 | Direct |
Footnotes
F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 29, 2020.
F2: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.
F3: Sales prices range from $30.66 to $31.60 per share, inclusive.
F4: Sales prices range from $32.32 to $32.93 per share, inclusive